Skip to main content

Advertisement

SpringerLink
Log in

A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer

  • PHASE II STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Background: The combination of doxorubicin and interferon alpha is supported by preclinical data. We sought to evaluate the efficacy of this combination in patients with advanced thyroid cancer. Patients and methods: Patients with locally recurrent or metastatic, radioiodine- refractory thyroid cancer, excluding medullary carcinoma, were treated with interferon alpha-2b 12 million units/m2 subcutaneously on days 1–5 and doxorubicin 40 mg/m2 intravenously, on day 3, every 28 days. Results: 17 patients, 15 with well differentiated and 2 with anaplastic thyroid carcinoma, were enrolled; median age was 69 years. Three patients had received radiation plus low dose doxorubicin previously. In 16 patients assessable for response, 1 patient (6%), who had follicular carcinoma, achieved a partial response and 10 patients (62.5%) stable disease as best response. Median time to progression was 5.9 months and median overall survival 26.4 months. In 14 evaluable patients, 5 (36%) had a thyroglobulin response (30% or more reduction in serum levels). Grade 3/4 neutropenia occurred in 76% of patients and neutropenic fever in 24%. Other grade 3/4 adverse events included fatigue (41%), rigors (18%), fever (6%), nausea/vomiting (29%), anorexia (29%), stomatitis (24%), vision disturbances (18%), neuropathy (18%), and hyponatremia (6%). One patient developed heart failure. Conclusions: Doxorubicin and interferon alpha was associated with considerable toxicities but modest antitumor activity in patients with advanced, non-medullary thyroid cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66

    Article  PubMed  Google Scholar 

  2. Palme CE, Waseem Z, Raza SN, Eski S, Walfish P, Freeman JL (2004) Management and outcome of recurrent well-differentiated thyroid carcinoma. Arch Otolaryngol Head Neck Surg 130(7):819–824

    Article  PubMed  Google Scholar 

  3. Robbins J, Merino MJ, Boice JD, Jr., et al (1991) Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 115(2):133–147

    PubMed  CAS  Google Scholar 

  4. McConahey WM, Hay ID, Woolner LB, van Heerden JA, Taylor WF (1986) Papillary thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 61(12):978–996

    PubMed  CAS  Google Scholar 

  5. Holt E (2007) Controversies in the surveillance of patients with well differentiated thyroid cancer. Curr Opin Oncol 19(1):6–10

    Article  PubMed  Google Scholar 

  6. Samaan NA, Schultz PN, Haynie TP, Ordonez NG (1985) Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 60(2):376–380

    Article  PubMed  CAS  Google Scholar 

  7. Kim JH, Leeper RD (1987) Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60(10):2372–2375

    Article  PubMed  CAS  Google Scholar 

  8. Nilsson O, Lindeberg J, Zedenius J et al (1998) Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg 22(7):725–730

    Article  PubMed  CAS  Google Scholar 

  9. Cornett WR, Sharma AK, Day TA et al. (2007) Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep 9(2):152–158

    Article  PubMed  Google Scholar 

  10. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A (1985) randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56(9):2155–2160

    Article  PubMed  CAS  Google Scholar 

  11. Williams SD, Birch R, Einhorn LH (1986) Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 70(3):405–407

    PubMed  CAS  Google Scholar 

  12. Scherubl H, Raue F, Ziegler R (1990) Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 116(1):21–23

    Article  PubMed  CAS  Google Scholar 

  13. Hoskin PJ, Harmer C (1987) Chemotherapy for thyroid cancer. Radiother Oncol 10(3):187–194

    Article  PubMed  CAS  Google Scholar 

  14. Liaw KY, Chang-Chien Y, Chen YC, Deng JS (1980) Impaired cell-mediated immunity function in thyroid cancer. Cancer 46(2):285–288

    Article  PubMed  CAS  Google Scholar 

  15. Lissoni P, Barni S, Tancini G et al (1995) Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors. Oncology 520(2):163–166

    Google Scholar 

  16. Moschos S, Varanasi S, Kirkwood JM (2005) Interferons in the treatment of solid tumors. Cancer Treat Res 126:207–241

    Article  PubMed  Google Scholar 

  17. Caraccio N, Giannini R, Cuccato S et al (2005) Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocrinol Metab 90(2):1156–1162

    Article  PubMed  CAS  Google Scholar 

  18. Lahat N, Sheinfeld M, Sobel E, Kinarty A, Kraiem Z (1992) Divergent effects of cytokines on human leukocyte antigen-DR antigen expression of neoplastic and non-neoplastic human thyroid cells. Cancer 69(7):1799–1807

    Article  PubMed  CAS  Google Scholar 

  19. Welander CE, Morgan TM, Homesley HD, Trotta PP, Spiegel RJ (1985) Combined recombinant human interferon alpha 2 and cytotoxic agents studied in a clonogenic assay. Int J Cancer 35(6):721–729

    Article  PubMed  CAS  Google Scholar 

  20. Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50(12):3473–3486

    PubMed  CAS  Google Scholar 

  21. Lupoli G, Cascone E, Arlotta F et al (1996) Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide. Cancer 78(5):1114–1118

    Article  PubMed  CAS  Google Scholar 

  22. Green MD, Speyer JL, Hochster HS et al (1988) Phase I trial of escalating dose doxorubicin administered concurrently with alpha 2-interferon. Cancer Res 48(9):2574–2578

    PubMed  CAS  Google Scholar 

  23. Sarosy GA, Brown TD, Von Hoff DD et al (1986) Phase I study of alpha 2-interferon plus doxorubicin in patients with solid tumors. Cancer Res 46(10):5368–5371

    PubMed  CAS  Google Scholar 

  24. Creagan ET, Frytak S, Long HJ, Kvols LK (1989) Phase I study of recombinant leukocyte A interferon (IFN-alpha 2A, Roferon-A) with doxorubicin in advanced malignant disease. Cancer 64(5):1034–1037

    Article  PubMed  CAS  Google Scholar 

  25. Pacini F, Lari R, Mazzeo S, Grasso L, Taddei D, Pinchera A (1985) Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 23(4):405–411

    CAS  Google Scholar 

  26. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214

    Article  PubMed  CAS  Google Scholar 

  27. Siragusa M, Zerilli M, Iovino F et al (2007) MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Cancer Res 67(11):5522–5530

    Article  PubMed  CAS  Google Scholar 

  28. Lu YS, Hsu C, Li CC et al (2004) Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma. Hepatogastroenterology 51(57):815–819

    PubMed  CAS  Google Scholar 

  29. Upham JW, Musk AW, van Hazel G, Byrne M, Robinson BW (1993) Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust N Z J Med 23(6):683–687

    PubMed  CAS  Google Scholar 

  30. Welander CE (1987) Overview of preclinical and clinical studies of interferon alfa-2b in combination with cytotoxic drugs. Invest New Drugs 5 (Suppl):S47–S59

    PubMed  CAS  Google Scholar 

  31. Cohen E, Vokes E, Rosen L et al (2007) A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers. J Clin Oncol 25(18S):6008

    Google Scholar 

  32. Sherman SI, Schlumberger MJ, Droz J et al (2007) Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). J Clin Oncol 25(18S):6017

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, UPMC Cancer Pavilion, 5th Floor, Pittsburgh, PA, 15232, USA

    Athanassios Argiris & Michalis V. Karamouzis

  2. St. Luke’s Health System, Bethlehem, PA, USA

    Sanjiv S. Agarwala

  3. University of Minnesota Medical Center, Minneapolis, MN, USA

    Lynn A. Burmeister

  4. Division of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA

    Sally E. Carty

Authors
  1. Athanassios Argiris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sanjiv S. Agarwala
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michalis V. Karamouzis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lynn A. Burmeister
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sally E. Carty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Athanassios Argiris.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Argiris, A., Agarwala, S.S., Karamouzis, M.V. et al. A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer. Invest New Drugs 26, 183–188 (2008). https://doi.org/10.1007/s10637-007-9091-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-007-9091-2

Keywords

Search

Navigation